{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:47:54Z","timestamp":1781531274335,"version":"3.54.5"},"reference-count":125,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003401","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Alagoas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cpcardiol.2024.102480","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:23:46Z","timestamp":1708514626000},"page":"102480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of the cardioprotective drugs class based on pathophysiology of myocardial infarction: A comprehensive review"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-3552","authenticated-orcid":false,"given":"Emanuel Ten\u00f3rio","family":"Paulino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2024.102480_bib0018","article-title":"European society of hypertension- European Society of cardiology guidelines for the management of arterial hypertension","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0022","series-title":"The Atlas of Heart Disease and Stroke","author":"Mackay","year":"2004"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0025","unstructured":"EHNHEART. European cardiovascular disease statistics 2017 edition. Available: http:\/\/www.ehnheart.org\/component\/downloads\/downloads\/2452. Accessed on 07\/08\/2017."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0001","first-page":"351","volume":"1","author":"Shephered","year":"1979"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0002","first-page":"3","article-title":"Basic cardiovascular system","author":"Opie","year":"2004","journal-title":"Heart Physiology: From Cell to Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0003","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/172530b0","article-title":"Sctrutural basis of the cross-striation in muscle","volume":"172","author":"Hanson","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0004","series-title":"Physiology of the Heart","first-page":"3","article-title":"Sctructure of the heart and cardiac muscle","author":"Katz","year":"2010"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1152\/ajpregu.00333.2009","article-title":"Early life stress down regulates endothelin receptor expression and enhances acute stress-mediated blood pressure responses in adult rats","volume":"299","author":"Loria","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0006","series-title":"Histologia comparada","first-page":"67","article-title":"Tecido muscular","author":"Ludovico","year":"1998"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0007","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1590\/S0066-782X2006001800015","article-title":"Tend\u00eancia do risco de morte por doen\u00e7as circulat\u00f3rias, cerebrovasculares e isqu\u00eamicas do cora\u00e7\u00e3o em treze estados do Brasil, de 1980 a 1998","volume":"87","author":"Mansur","year":"2006","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0008","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/01.RES.78.2.262","article-title":"Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure","volume":"78","author":"Kaab","year":"1996","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0009","first-page":"796","article-title":"Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance","volume":"38","author":"Hundley","year":"2001","journal-title":"Clinical Study: Heart Failure"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/eye.1994.19","article-title":"Vessel diameter changes during the cardiac cycle","volume":"8","author":"Chen","year":"1994","journal-title":"Eye"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0011","series-title":"Tratado de Fisiologia Aplicado \u00e0s Ci\u00eancias M\u00e9dicas","first-page":"522","article-title":"Fisiologia do cora\u00e7\u00e3o","author":"Douglas","year":"2006"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0012","series-title":"Fundamentos de Fisiologia","first-page":"103","article-title":"O m\u00fasculo card\u00edaco: o cora\u00e7\u00e3o como uma bomba e a fun\u00e7\u00e3o das valvas card\u00edacas","author":"Guyton","year":"2012"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0013","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.RES.78.5.737","article-title":"\u03b11-adren\u00e9rgic receptors subtypes, molecular structure, functions and signaling","volume":"78","author":"Graham","year":"1996","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0014","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/01.CIR.99.18.2458","article-title":"\u03b22-adrenergic cAMP signaling is uncoupled from phosporilation of cytoplasmatic proteins in canine heart","volume":"99","author":"Kuschel","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1054-3589(08)60777-2","article-title":"Mechanisms of \u03b2-adrenergic receptors desentization and resensitization","volume":"42","author":"Lefkowitz","year":"1997","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0017","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa003417","article-title":"Impact of high normal blood pressure on the risk of cardiovascular disease","volume":"345","author":"Vasan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0019","first-page":"1","article-title":"IV Diretrizes Brasileiras de hipertens\u00e3o arterial - sociedade Brasileira de hipertens\u00e3o","volume":"95","year":"2010","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0020","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high- risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0021","first-page":"e618","article-title":"Fourth universal definition of myocardial infarction","volume":"138","author":"Thygesen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0023","first-page":"1","article-title":"Deaths: final data for 2006","volume":"57","author":"Heron","year":"2009","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0024","series-title":"Morbidity and Mortality:2009. Chart Book on Cardiovascular, Lung and Blood Diseases","year":"2009"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0026","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1001\/jama.283.24.3223","article-title":"Prevalence, clinical characteristics and mortality among patients with myocardial infarction presenting without chest pain","volume":"283","author":"Canto","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0027","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.161.5.685","article-title":"Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacological Interventions in the Elderly (TONE)","volume":"161","author":"Appel","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0028","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0049-3848(97)00143-6","article-title":"Fluvastatin and tissue factor pathway inhibitor in type IIa and IIb hyperlipidemia and in acute myocardial infarction","volume":"87","author":"Lorena","year":"1997","journal-title":"Thromb Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0029","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2105\/AJPH.89.3.292","article-title":"Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century","volume":"89","author":"Nieto","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3923\/ijp.2008.1.10","article-title":"Chronic administration of Tribulus terrestris Linn. Extract improves cardiac function and attenuates myocardial infarction in rats","volume":"4","author":"Ojha","year":"2008","journal-title":"Int J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0031","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0165-1838(91)90042-2","article-title":"The effects of interleukin-1 on the activity of adrenal, splenic and renal sympatetic nerves in the rats","volume":"36","author":"Niijima","year":"1991","journal-title":"J Auton Nerv Syst"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0008-6363(01)00434-5","article-title":"The inflammatory response in myocardial infarction","volume":"53","author":"Frangogiannis","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0033","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1161\/01.CIR.98.21.2334","article-title":"Sudden cardiac dealth","volume":"98","author":"Zipes","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0034","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.CIR.0000044941.13346.74","article-title":"Effect of adrenergic stimulation on action potencial duration restitution in humans","volume":"107","author":"Taggar","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00041552-200409000-00006","article-title":"Counteracting the sympathetic nervous system in the essential hypertension","volume":"13","author":"Grass","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0036","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.CIR.0000081775.72651.B6","article-title":"Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy","volume":"108","author":"Schalaich","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1124\/pr.56.1.2","article-title":"Autonomic nervous system pharmacogenomics: a progress report","volume":"56","author":"Kirstein","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0038","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/01.CIR.93.9.1667","article-title":"Cardiac sympathetic nerve function in congestive heart failure","volume":"93","author":"Eisenhofer","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0039","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.85.2.790","article-title":"Adrenergic effects on the biology of the adult mammalia cardiocyte","volume":"85","author":"Mann","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/01.CIR.98.13.1329","article-title":"Norepinephrine stimulate apoptosis in adult rat ventricular myocytes by activation \u03b2-adrenergic pathway","volume":"98","author":"Communal","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0041","first-page":"16","article-title":"Neurohumoral activation and progression of heart failure","volume":"32","author":"Francis","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0042","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/ajpregu.00317.2002","article-title":"Heart failure and the brain: new perspectives","volume":"284","author":"Felder","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0043","first-page":"11","article-title":"Beta-blockers in cardioprotection after acute myocardial infarction","volume":"7","author":"Pavlovic","year":"2000","journal-title":"Sci J"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0044","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cardiores.2004.04.031","article-title":"Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence","volume":"63","author":"Selvetella","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1749-6632.1995.tb17414.x","article-title":"Signaling pathways for cardiac growth and hypertrophy","volume":"752","author":"Lembo","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0046","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.phrs.2009.11.012","article-title":"Molecular targets and regulators of cardiac hypertrophy","volume":"61","author":"Rohini","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0047","first-page":"414","article-title":"Influ\u00eancia de fatores ambientais e gen\u00e9ticos na hipertrofia e remodelamentos card\u00edacos na hipertens\u00e3o arterial","volume":"8","author":"Junior","year":"2001","journal-title":"Rev Bras Hipertens"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0048","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/01.CIR.0000029923.57048.61","article-title":"Guanylyl Cyclase-A inhibits angiotensin II type 1A. Receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart","volume":"106","author":"Li","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0049","first-page":"552","article-title":"Estudo evolutivo da morfologia e fun\u00e7\u00e3o card\u00edaca em ratos submetidos a estenose a\u00f3rtica supravalvar","volume":"81","author":"Ribeiro","year":"2003","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCRESAHA.110.220038","article-title":"The IP3 receptor regulates cardiac hypertrofic in response to select stimuli","volume":"107","author":"Nakayama","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0051","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1113\/expphysiol.2009.047332","article-title":"Therapeutics strategies for targeting excessive central sympathetic activation in human hypertension","volume":"95","author":"Fisher","year":"2010","journal-title":"Exp Physiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0052","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/HYPERTENSIONAHA.108.121467","article-title":"Sympathetic and baroreflex cardiovascular control in hypertension related left ventricular disfunctions","volume":"53","author":"Grassi","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0053","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/hrt.75.4.330","article-title":"Cardioprotection: definition, classification,and fundamental principles","volume":"75","author":"Kuibler","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0054","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nm0898-929","article-title":"Regenerating functional myocardium: improved performance after skeletal myoblast transplantation","volume":"4","author":"Taylor","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0055","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","article-title":"Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions","volume":"113","author":"Sanganalmath","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0056","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cvr\/cvp146","article-title":"Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium","volume":"83","author":"Smits","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0057","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pharmthera.2014.05.005","article-title":"Novel therapeutic strategies for cardioprotection","volume":"144","author":"Sluitjer","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0058","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(11)61590-0","article-title":"Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial","volume":"378","author":"Bolli","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0059","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(12)60195-0","article-title":"Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial","volume":"379","author":"Makkar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0060","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.yjmcc.2010.08.005","article-title":"Paracrine mechanisms of stem cell reparative and regenerative actions in the heart","volume":"50","author":"Mirotsou","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0061","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1006\/jmcc.2001.1462","article-title":"Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research","volume":"33","author":"Bolli","year":"2001","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0062","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/01.RES.0000065441.72685.29","article-title":"Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism","volume":"92","author":"LI","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0063","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/107424840501000405","article-title":"A vigilant, hypoxiaregulated heme oxygenase-1 gene vector in the heart limits cardiac injury after ischemia\u2013reperfusion in vivo","volume":"10","author":"Tang","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0064","doi-asserted-by":"crossref","first-page":"H2905","DOI":"10.1152\/ajpheart.00323.2006","article-title":"In vivo gene delivery of HSP70i by adenovirus and adeno-associated virus preserves contractile function in mouse heart following ischemia\u2013reperfusion","volume":"291","author":"Belke","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbrc.2003.09.160","article-title":"Bcl-xL gene transfer protects the heart against ischemia\/reperfusion injury","volume":"311","author":"Huang","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0066","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1152\/physiolgenomics.00058.2001","article-title":"Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha","volume":"8","author":"Jiang","year":"2002","journal-title":"Physiol Genom"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0067","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/hum.2007.036","article-title":"Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia\/reperfusion-induced injury and attenuates its postischemic failure","volume":"18","author":"Duan","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0068","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jgm.347","article-title":"Strategic advantages of insulin-like growth factor-I expression for cardioprotection","volume":"5","author":"Chao","year":"2003","journal-title":"J Gene Med"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0069","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00395-010-0102-7","article-title":"Hepatocyte growth factor\/Met gene transfer in cardiac stem cells\u2014potential for cardiac repair","volume":"105","author":"Madonna","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/sj.gt.3303071","article-title":"Overexpression of TGFbeta1 by adeno-associated virus type-2 vector protects myocardium from ischemia\u2013reperfusion injury","volume":"15","author":"Dandapat","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0071","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jbiotec.2011.05.014","article-title":"Stem cells and growth factor delivery systems for cardiovascular disease","volume":"154","author":"Madonna","year":"2011","journal-title":"J Biotechnol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0072","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/molecules27041320","article-title":"The role of flavonoids as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: a review","volume":"27","author":"Syahputra","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0073","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mi.6.1.7","article-title":"Resveratrol in cardioprotection: a therapeutic promises of alternative medicines","volume":"6","author":"Das","year":"2006","journal-title":"Mol Interv"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2012.00141","article-title":"Resveratrol: a French paradox revisited","author":"Catalgol","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0099","unstructured":"Warnicka, J.W. Infarto Agudo do Mioc\u00e1rdio. Dispon\u00edvel em: https:\/\/www.msdmanuals.com\/pt-pt\/profissional\/dist%C3%BArbios-cardiovasculares\/doen%C3%A7a-arterial-coronariana\/infarto-agudo-do-mioc%C3%A1rdio-iam. Accessed on: 14\/12\/2023."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3233\/CH-2011-1424","article-title":"Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease","volume":"50","author":"Magyar","year":"2012","journal-title":"Clin Hemorheol Microcirc"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102480_bib0076","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.febslet.2008.12.037","article-title":"Targeting STAT-1 by myricetin and delphinidin provides efficient protection of the hearts from ischemia-reperfusion induced injury","volume":"583","author":"Scarabelli","year":"2009","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0077","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jnutbio.2009.12.004","article-title":"Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids","volume":"21","author":"Adkins","year":"2010","journal-title":"J Nutr Biochem."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0078","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jjcc.2015.08.002","article-title":"Cardioprotective mechanism of omega-3 polyunsaturated fatty acids","volume":"67","author":"Endo","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0079","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10974-016-9459-z","article-title":"Cardioprotective effects of omega 3 fatty acids: origin of the variability","volume":"38","author":"Roy","year":"2017","journal-title":"J Muscle Res Cell Motil"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102480_bib0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/md16070234","article-title":"Cardioprotective effects of omega-3 polyunsaturated fatty acids: dichotomy between experimental and clinical studies","volume":"16","author":"Desnoyers","year":"2018","journal-title":"Mar Drugs"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0081","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.CIR.76.5.1135","article-title":"Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon","volume":"76","author":"Olafsson","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0082","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.00310","article-title":"Adenosine receptor-mediated cardioprotection\u2014current limitations and future directions","volume":"9","author":"Lasley","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0025618","article-title":"The role of muscarinic receptors in the beneficial effects of adenosine against myocardial reperfusion injury in rats","volume":"6","author":"Sun","year":"2011","journal-title":"Plos One."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0084","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00395-006-0587-2","article-title":"Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts","volume":"101","author":"Yang","year":"2006","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0085","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(07)61634-1","article-title":"Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials","volume":"370","author":"Kitakaze","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0100","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1006\/jmcc.2001.1462","article-title":"Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research","volume":"33","author":"Bolli","year":"2001","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0086","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1590\/S0100-879X2003000100012","article-title":"Protective effects of centrally acting sympathomodulatory drugs on myocardial ischaemia induced by sympathetic overactivity in rabbits","volume":"36","author":"Catelli","year":"2003","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0087","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1470320308353059","article-title":"Cardioprotective effects of benazepril, an angiotensin-converting enzyme inhibitor, in an ischaemia-reperfusion model of myocardial infarction in rats","volume":"10","author":"Charan-Sahoo","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0088","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00005344-200101000-00008","article-title":"Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction\u2013induced heart failure in rats","volume":"37","author":"Sandmann","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0089","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-2999(99)00050-3","article-title":"The cardioprotective effects of nitroglycerin-induced preconditioning are mediated by calcitonin gene-related peptide","volume":"369","author":"Hu","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0057757","article-title":"The novel MAS agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats","volume":"8","author":"Savergnini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0091","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.regpep.2007.10.001","article-title":"Protective effects of GLP-1 analogues exendin-4 and GLP-1(9\u201336) amide against ischemia\u2013reperfusion injury in rat heart","volume":"146","author":"Sonne","year":"2008","journal-title":"Regulatory Peptides. V."},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102480_bib0092","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury","volume":"53","author":"Timmers","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0093","series-title":"Management of Myocardial Reperfusion Injury","first-page":"293","article-title":"Future perspectives","volume":"1","author":"Kaski","year":"2012"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0094","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0095","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ijcard.2013.04.013","article-title":"Do exenatide truly improve the myocardial infarction size?","volume":"168","author":"Woo","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0096","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGTL-2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Fillippatos","year":"2019","journal-title":"Postgrad Med"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0097","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1076\/phbi.40.5.346.8461","article-title":"Antioxidants in medicines and spices as cardioprotective agents in Tibetan highlanders","volume":"40","author":"Owen","year":"2002","journal-title":"Pharm Biol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0098","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0026-895X(24)12861-1","article-title":"The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption","volume":"61","author":"Orallo","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0101","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mi.6.1.7","article-title":"Resveratrol in cardioprotection: a therapeutic promises of alternative medicines","volume":"6","author":"Das","year":"2006","journal-title":"Molecules interventions"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2012.00141","article-title":"Resveratrol: a French paradox revisited","author":"Catalgol","year":"2012","journal-title":"Frontiers in pharmacology"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3233\/CH-2011-1424","article-title":"Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease","volume":"50","author":"Magyar","year":"2012","journal-title":"Clinical Hemorheology and microcirculation"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102480_bib0104","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.febslet.2008.12.037","article-title":"Targeting STAT-1 by myricetin and delphinidin provides efficient protection of the hearts from ischemia-reperfusion induced injury","volume":"583","author":"Scarabelli","year":"2009","journal-title":"FEBS letters"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jnutbio.2009.12.004","article-title":"Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids","volume":"21","author":"Adkins","year":"2010","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jjcc.2015.08.002","article-title":"Cardioprotective mechanism of omega-3 polyunsaturated fatty acids","volume":"67","author":"Endo","year":"2016","journal-title":"Journal of Cardiology"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0107","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10974-016-9459-z","article-title":"Cardioprotective effects of omega 3 fatty acids: origin of the variability","volume":"38","author":"Roy","year":"2017","journal-title":"J Muscle Res Cell Motil"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102480_bib0108","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/md16070234","article-title":"Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids: Dichotomy between Experimental and Clinical Studies","volume":"16","author":"Desnoyers","year":"2018","journal-title":"Mar Drugs"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0109","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.CIR.76.5.1135","article-title":"Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon","volume":"76","author":"Olafsson","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.00310","article-title":"Adenosine Receptor-Mediated Cardioprotection\u2014Current Limitations and Future Directions","volume":"9","author":"Lasley","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0025618","article-title":"The Role of Muscarinic Receptors in the Beneficial Effects of Adenosine against Myocardial Reperfusion Injury in Rats","volume":"6","author":"Sun","year":"2011","journal-title":"Plos One."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0112","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00395-006-0587-2","article-title":"Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts","volume":"101","author":"Yang","year":"2006","journal-title":"Basic Research in Cardiology"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0113","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(07)61634-1","article-title":"Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials","volume":"370","author":"Kitakaze","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1590\/S0100-879X2003000100012","article-title":"Protective effects of centrally acting sympathomodulatory drugs on myocardial ischaemia induced by sympathetic overactivity in rabbits","volume":"36","author":"Catelli","year":"2003","journal-title":"Brazilian journal of medical and biological research"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1470320308353059","article-title":"Cardioprotective effects of benazepril, an angiotensin-converting enzyme inhibitor, in an ischaemia-reperfusion model of myocardial infarction in rats","volume":"10","author":"Sahoo","year":"2009","journal-title":"Journal of Renin-Angiotensin-Aldosterone System"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0116","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00005344-200101000-00008","article-title":"Calcium Channel Blockade Limits Cardiac Remodeling and Improves Cardiac Function in Myocardial Infarction\u2013Induced Heart Failure in Rats","volume":"37","author":"Sandmann","year":"2001","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0117","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-2999(99)00050-3","article-title":"The cardioprotective effects of nitroglycerin-induced preconditioning are mediated by calcitonin gene-related peptide","volume":"369","author":"Hu","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0118","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.regpep.2007.10.001","article-title":"Protective effects of GLP-1 analogues exendin-4 and GLP-1(9\u201336) amide against ischemia\u2013reperfusion injury in rat heart","volume":"146","author":"Sonne","year":"2008","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0119","first-page":"501","volume":"53","author":"Timmers","year":"2009"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0120","first-page":"293","article-title":"Future Perspectives","volume":"1","author":"Kaski","year":"2012","journal-title":"Management of Myocardial Reperfusion Injury"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0121","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0122","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ijcard.2013.04.013","article-title":"Do exenatide truly improve the myocardial infarction size?","volume":"168","author":"Woo","year":"2013","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0123","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT-2 Inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Fillippatos","year":"2019","journal-title":"Postgrad Med"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0124","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1076\/phbi.40.5.346.8461","article-title":"Antioxidants in Medicines and Spices as Cardioprotective Agents in Tibetan Highlanders","volume":"40","author":"Owen","year":"2002","journal-title":"Pharmaceutical biology"},{"key":"10.1016\/j.cpcardiol.2024.102480_bib0125","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0026-895X(24)12861-1","article-title":"The Possible Implication of trans-Resveratrol in the Cardioprotective Effects of Long-Term Moderate Wine Consumption","volume":"61","author":"Orallo","year":"2002","journal-title":"Molecular Pharmacology"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:43:17Z","timestamp":1758940997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":125,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0146280624001191"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102480","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of the cardioprotective drugs class based on pathophysiology of myocardial infarction: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102480"}}